{"groups":[{"description":"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m\\^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m\\^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.\n\nMaintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m\\^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy.","id":"FG000","title":"Lenalidomide, Subcutaneous Bortezomib, Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Did not receive treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"Safety"},{"achievements":[{"groupId":"FG000","numSubjects":"41"}],"type":"Progression-free Survival Evaluable"},{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"Evaluable for Induction Response"},{"achievements":[{"groupId":"FG000","numSubjects":"15"}],"type":"Received Autologous Stem Cell Transplant (ASCT)"},{"achievements":[{"groupId":"FG000","numSubjects":"38"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Induction"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"23"}],"type":"Remaining on Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"38"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"Safety"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Given treatment duration is not a fixed duration, all participants are considered as 'Not Completed'. Reasons off-treatment are provided for all participants not still on treatment as of the date of data extraction.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"38"}],"type":"NOT COMPLETED"}],"title":"Maintenance"}],"recruitmentDetails":"Participants were enrolled from December 2015 to June 2017."}